MEDI3902 500 mg (N = 16) | MEDI3902 1500 mg (N = 85) | Placebo (N = 83) | RRRa | 80% CIa | P valuea | |
---|---|---|---|---|---|---|
Primary endpoint | ||||||
P. aeruginosa Pneumonia | 2 (12.5%) | 19 (22.4%) | 15 (18.1%) | − 23.7% | − 83.8 to 16.8% | 0.491 |
Exploratory endpoints of interest (FDA) | ||||||
All-cause pneumoniab | 3 (18.8%) | 25 (29.4%) | 17 (20.5%) | − 43.6% | − 104 to -1.1% | 0.186 |
All-cause pneumonia or deathc | 4 (25.0%) | 30 (35.3%) | 22 (26.5%) | − 33.2% | − 79.8 to 1.4% | 0.222 |